FDA Approves First Cell-Based Gene Therapy For Rare Skin Disorder Authored by Zachary Stieber via The Epoch Times (emphasis ours), The Food and Drug Administration (FDA) has approved Zevaskyn, a gene therapy for a rare skin disorder, the company that makes the product said on April 29. The U.S. Food and Drug Administration building in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times Regulators approved Zevaskyn for adults and children with recessive dystrophic epidermolysis bullosa, a disorder that leaves skin fragile and prone to blistering. Severe cases of the disorder can result in loss of vision and… — Continue at ZeroHedge News : Read More
